Vivek Subbiah

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 6:e18424. 2011
  2. doi request reprint Adolescent oncology: who cares?-the new KID on the block
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA
    Support Care Cancer 18:771-3. 2010
  3. pmc Gastric adenocarcinoma in children and adolescents
    Vivek Subbiah
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Pediatr Blood Cancer 57:524-7. 2011
  4. pmc Ewing's sarcoma: overcoming the therapeutic plateau
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics and Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Discov Med 13:405-15. 2012
  5. doi request reprint Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States Electronic address
    Lung Cancer 89:76-9. 2015
  6. doi request reprint STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
    Vivek Subbiah
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutic Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8 3038, Box 0455, Houston, TX, 77030, USA
    J Hematol Oncol 8:66. 2015
  7. pmc Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston 77030, Texas, USA
    J Hematol Oncol 7:52. 2014
  8. pmc Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine and Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Curr Oncol Rep 16:401. 2014
  9. pmc Targeted Therapy of Ewing's Sarcoma
    Vivek Subbiah
    Department of Pediatrics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Sarcoma 2011:686985. 2011
  10. pmc Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8, 3038, Box 0455, Houston, TX 77030, USA
    J Hematol Oncol 7:8. 2014

Collaborators

Detail Information

Publications37

  1. pmc Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 6:e18424. 2011
    ..We performed morphoproteomic profiling to better understand response/resistance mechanisms of Ewing's sarcoma to IGF1R inhibitor-based therapy...
  2. doi request reprint Adolescent oncology: who cares?-the new KID on the block
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA
    Support Care Cancer 18:771-3. 2010
    ..The need for optimizing and personalizing care in this age group is highlighted...
  3. pmc Gastric adenocarcinoma in children and adolescents
    Vivek Subbiah
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Pediatr Blood Cancer 57:524-7. 2011
    ..Initial chemotherapy was mainly platinum-based. Median time to progression was 4 months. The only long-term survivor was a patient with localized disease who had complete surgical removal of primary tumor...
  4. pmc Ewing's sarcoma: overcoming the therapeutic plateau
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics and Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Discov Med 13:405-15. 2012
    ....
  5. doi request reprint Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States Electronic address
    Lung Cancer 89:76-9. 2015
    ..Our case report forms the first evidence of blood-brain barrier penetration by vandetanib in combination with everolimus. Further research is required in this setting. ..
  6. doi request reprint STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion
    Vivek Subbiah
    Division of Cancer Medicine, Department of Investigational Cancer Therapeutic Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8 3038, Box 0455, Houston, TX, 77030, USA
    J Hematol Oncol 8:66. 2015
    ..To our knowledge, this case represents the first report of clinical response to targeted therapy in a tumor harboring a DCTN1-ALK fusion protein...
  7. pmc Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston 77030, Texas, USA
    J Hematol Oncol 7:52. 2014
    ..The management of this refractory population remains challenging and approximately 400 patients continue to die every year of this refractory disease in the United States...
  8. pmc Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine and Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Curr Oncol Rep 16:401. 2014
    ....
  9. pmc Targeted Therapy of Ewing's Sarcoma
    Vivek Subbiah
    Department of Pediatrics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Sarcoma 2011:686985. 2011
    ..The successful application of this first-in-class protein-protein inhibitor in the clinic could become a model system for translocation-associated cancers such as EWS...
  10. pmc Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8, 3038, Box 0455, Houston, TX 77030, USA
    J Hematol Oncol 7:8. 2014
    ....
  11. pmc Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1)
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    PLoS ONE 8:e68985. 2013
    ..We performed morphoproteomic profiling of DSRCT (EWS-WT1), Ewing's sarcoma (EWS-FLI1) and Wilms' tumor (WT1) to better understand the signaling pathways for selecting future targeted therapies...
  12. pmc Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, Texas 77030, USA
    Mol Cancer Ther 11:2541-6. 2012
    ....
  13. pmc How watching the movie Zombieland helps treatment of cancer in teenagers
    Vivek Subbiah
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Cancer Educ 27:188-91. 2012
    ..Communication is the foremost way to keep all doors open in this unique physician-patient relationship. One such approach is "movie therapy" using characters and actions as metaphors for describing cancer and cancer treatment...
  14. doi request reprint Phase 1 clinical trials for sarcomas: the cutting edge
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics A Phase I Program, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 23:352-60. 2011
    ..This review outlines recent phase 1 trials involving sarcoma patients, explores current challenges and highlights future opportunities in sarcoma developmental therapeutics...
  15. ncbi request reprint Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target?
    Vivek Subbiah
    Expert Opin Investig Drugs 20:1471-7. 2011
    ..Matching patients with these agents based on molecular profiling/signatures will be essential for the proper development of this type of targeted agent...
  16. pmc Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit
    Débora de Melo Gagliato
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Breast Cancer 14:468-74. 2014
    ..We describe MET mutation and amplification rates in a BC cohort of patients referred to a Phase I Unit...
  17. doi request reprint Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
    Ishwaria M Subbiah
    Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 6:28453-62. 2015
    ..Given the rapid advanced in drug development and emergence of novel agents, we analyzed the characteristics and outcomes of HCC patients treated on early phase trials with an emphasis on targeted therapies...
  18. doi request reprint MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors
    Denis L F Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, TX Electronic address
    Clin Genitourin Cancer 13:e19-26. 2015
    ..The purpose of this study was to determine the prevalence of MET amplification and mutation among GU malignancies and its association with clinical factors and responses to c-MET inhibitors...
  19. pmc Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e93676. 2014
    ..Very few somatic mutations have been reported in ES, and none have been identified in DSRCT. The aim of this study is to explore potential actionable mutations in ES and DSRCT...
  20. pmc FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
    Denis L Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e89388. 2014
    ..Preclinical data suggest that FBXW7 mutations sensitize cells to mTOR inhibitors. Clinicopathologic characteristics of cancer patients with FBXW7 mutations and their responses to mTOR inhibitors remain unknown...
  21. pmc MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
    Denis L Fontes Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, USA
    Oncotarget 5:1837-45. 2014
    ..In conclusion, MET abnormalities can be found in a small group of patients with GE adenocarcinoma and further studies are necessary to better characterize the prognostic and predictive impact of MET alterations. ..
  22. pmc Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:884-9. 2013
    ..Our pilot data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma, a disease of young people, and their presence may have implications for therapy. ..
  23. pmc Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  24. doi request reprint Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
    Chad Tang
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:5956-63. 2014
    ..We hypothesized that chemotherapy synergizes with VEGF/VEGFR (VEGF/R) inhibitors in patients with advanced solid malignancies...
  25. pmc Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:2349-54. 2014
    ..The 'molecular individuality' of these tumors suggests that a customized strategy, using an "N-of-One" model of precision medicine, may represent an optimal approach for the treatment of patients with advanced tumors. ..
  26. doi request reprint Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach
    David Reynoso
    Department of Sarcoma Medical Oncology, M D Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA
    J Surg Oncol 101:327-33. 2010
    ....
  27. pmc Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report
    Jennifer Goldstein
    Division of Cancer Medicine, Medical Oncology and Hematology Fellowship Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    BMC Dermatol 15:2. 2015
    ..We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib-associated photoallergic dermatitis while enrolled on a phase 1 clinical trial...
  28. pmc Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery
    Chelsea C Pinnix
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 83:317-26. 2012
    ..treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation therapy (WAP-IMRT) as a component of multimodality therapy for DSCRT at a single institution...
  29. doi request reprint BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncotarget 6:26886-94. 2015
    ..In conclusion, our observations demonstrate that the Idylla test is rapid and has high concordance with other routinely used but more complex BRAF mutation-detecting tests. ..
  30. doi request reprint Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncotarget 6:40642-54. 2015
    ..We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy...
  31. pmc A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:95-102. 2014
    ..We also expand on the role of rapamycin analogs in oncology. This study supports a role for an immune-type pathogenesis that is amenable to immune modulating targeted therapy in refractory HL...
  32. doi request reprint Ewing's sarcoma: standard and experimental treatment options
    Vivek Subbiah
    Department of Sarcoma Medical Oncology, Division of Cancer Medicine, Labortory of Sarcoma Molecular Therapeutics, M D Anderson Cancer Center, Houston, TX, USA
    Curr Treat Options Oncol 10:126-40. 2009
    ..In this review, we discuss current standard-of-care for patients with Ewing's sarcoma and highlight the most promising experimental therapies in early-phase clinical trials...
  33. pmc Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities
    Denis L Fontes Jardim
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, FC8 3038, Box 0455, Houston, TX 77030, USA
    Orphanet J Rare Dis 8:112. 2013
    ....
  34. doi request reprint 99mTc-sestamibi scan differentiates tumor from other contrast enhancing tissue in choroid plexus tumors
    Vivek Subbiah
    Departments of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Pediatr Hematol Oncol 32:160-2. 2010
    ..Previous literature showed sestamibi to be helpful in detecting residual choroid plexus tumors resulting in further resection. Here, we report the first case to show that sestamibi scans can also help with the opposite decision...
  35. doi request reprint Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors
    Rashmi S Goswami
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 21:2644-51. 2015
    ..We used a clinical next-generation sequencing (NGS) hotspot mutation panel to investigate clonal evolution in paired primary and metastatic tumors...
  36. doi request reprint Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report
    Jennifer Goldstein
    Division of Cancer Medicine, Medical Oncology and Hematology Fellowship Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    BMC Dermatol 15:22. 2015
    ..We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib-associated photoallergic dermatitis while enrolled on a phase 1 clinical trial...
  37. doi request reprint Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome
    Vivek Subbiah
    Department of Pediatrics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Pediatr Blood Cancer 53:1349-51. 2009
    ..We present the clinical, radiological, and genetic (WT1 mutation analysis) of a 46 XY phenotypic female with Frasier syndrome with bilateral gonadoblastoma with dysgerminoma who developed pilocytic astrocytoma...